OrforglipronSemaglutideTirzepatide
Property
Categoryglp1glp1glp1
Typeotherpeptidepeptide
MechanismOral non-peptide GLP-1 receptor agonistGLP-1 receptor agonistDual GLP-1/GIP receptor agonist
Research Stageresearchfda-approvedfda-approved
Dosing Range12-45mg daily0.25-2.4mg weekly2.5-15mg weekly
FrequencyOnce daily (oral)Once weeklyOnce weekly
Half-Life~25-30 hours~7 days~5 days
Bioavailability / Route
Oral
Subcutaneous
Subcutaneous
Onset Time2-4 weeks2-4 weeks for appetite reduction2-4 weeks for appetite reduction
Key Benefits
Weight managementType 2 diabetesConvenient oral option
Weight managementType 2 diabetesAppetite control
Weight managementType 2 diabetesMetabolic health
Key Risks
NauseaDiarrheaVomiting
NauseaVomitingDiarrheaConstipation
NauseaDiarrheaDecreased appetiteVomiting
StorageRoom temperatureRefrigerated (2-8°C)Refrigerated (2-8°C)
Property comparison · Radar

Profile shape

Duration
Quick Onset
Versatility
Tolerability
Use Cases
Stackability
Typical dose ranges

Dose envelope

For educational purposes only. Consult a healthcare provider before starting any peptide protocol.